<DOC>
	<DOCNO>NCT03020771</DOCNO>
	<brief_summary>This study cover first trial Crimean-Congo Hemorrhagic fever virus ( CKKA ) vaccine human ( healthy volunteer ) , develop Turkey complete preclinical toxicology study perform experimental animal . Also , study Phase I , randomize , double-blind , national , single-center , placebo-controlled study design evaluate safety efficacy CKKA vaccine . A total 60 ( 12 + 48 ) healthy male and/or female volunteer participate study , study plan last approximately one year .</brief_summary>
	<brief_title>Phase I Study Evaluate Basic Pharmacodynamic , Pharmacological Toxicological Effects Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine Humans</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Hemorrhagic Fever , Crimean</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy , white 1855 age range , men and/or woman agree become pregnant 2 month start last vaccination Body weight limit exclude anorexia obesity ( The BMI limit accept study 18.530 kg /m2 ) According clinical standard laboratory test , physical spiritually healthy volunteer . The 20 day study vaccination apply volunteer Persons clinically significant liver , kidney , gastrointestinal , cardiovascular , psychiatric , pulmonary , hematologic , endocrinological , significant acute chronic abnormality medical history volunteer examination . Volunteers previously pulmonary infection previously use immunosuppressive drug ( include corticosteroid ) reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crimean-congo hemorrhagic fever</keyword>
	<keyword>vaccine</keyword>
	<keyword>human</keyword>
	<keyword>phase I</keyword>
</DOC>